---
schema_version: "secwatch.filing_event.v1"
accession: "0001034842-26-000016"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T21:58:50.974306+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Rigel Q4 net product sales $65.4M record; full year net income $367M, includes $245.9M tax benefit

## Summary
- Q4 2025 net product sales $65.4M (+41% YoY); TAVALISSE $45.6M (+47%), GAVRETO $10.2M (+27%), REZLIDHIA $9.6M (+29%).
- Full year 2025 net product sales $232M (+60% YoY); total revenue $294.3M.
- Q4 net income $268.1M ($14.72 basic EPS) includes $245.9M non-cash deferred tax benefit; FY net income $367M.
- 2026 guidance: total revenue $275-290M, net product sales $255-265M, expects positive net income.
- Cash $155.0M at Dec 31, 2025 vs $77.3M at Dec 31, 2024; R289 dose expansion enrollment on track for H2 2026 RP2D.

## SEC filing metadata
- accession: 0001034842-26-000016
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000103484226000016/0001034842-26-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000103484226000016/rigl-20260303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001034842-26-000016
- JSON: https://secwatch.observer/filing/0001034842-26-000016.json
- Plain text: https://secwatch.observer/filing/0001034842-26-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.